KTTA (STOCKS)
Pasithea Therapeutics Corp. Common Stock
$0.690000
-0.047000 (-6.38%)
Prev close: $0.737000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Tiago Reis Marques
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $16.16M
- Employees
- 4
- P/E (TTM)
- -0.14
- P/B (TTM)
- 0.45
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2024 (Q4)
|
$-2.41 | $0.00 | +0.0000 | +0.00% |
|
Mar 2022 (Q1)
|
$-1.40 | $-0.41 | -0.9920 | -243.14% |
|
Dec 2021 (Q4)
|
$2.40 | $-1.02 | +3.4200 | +335.29% |
Financial Statements
| Nonoperating Income/Loss | $366.21K |
| Research and Development | $6.75M |
| Operating Income/Loss | -$13.86M |
| Income/Loss From Continuing Operations After Tax | -$13.49M |
| Income/Loss From Continuing Operations Before Tax | -$13.49M |
| Net Income/Loss | -$13.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.49M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Average Shares | 15,348,802 |
| Diluted Average Shares | 15,348,802 |
| Assets | $13.63M |
| Current Assets | $5.53M |
| Prepaid Expenses | $1.29M |
| Other Current Assets | $4.24M |
| Noncurrent Assets | $8.10M |
| Intangible Assets | $6.84M |
| Other Non-current Assets | $1.26M |
| Liabilities | $1.42M |
| Current Liabilities | $1.38M |
| Noncurrent Liabilities | $46.87K |
| Equity | $12.21M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $12.21M |
| Liabilities And Equity | $13.63M |
| Net Cash Flow From Operating Activities | -$12.26M |
| Net Cash Flow From Operating Activities, Continuing | -$12.26M |
| Net Cash Flow From Investing Activities | $5.14M |
| Net Cash Flow From Investing Activities, Continuing | $5.18M |
| Net Cash Flow From Financing Activities | $7.07M |
| Net Cash Flow From Financing Activities, Continuing | $7.07M |
| Exchange Gains/Losses | $46.45K |
| Net Cash Flow | -$46.45K |
| Net Cash Flow, Continuing | -$92.89K |
| Comprehensive Income/Loss | -$13.45M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.44M |
| Other Comprehensive Income/Loss | -$6.17M |